biote Corp. (BTMD) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Medicinal Chemicals & Botanical ProductsSEC EDGAR biote Corp. (BTMD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
biote Corp. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY change data disclosed in MD&A
- • No profitability or margin figures reported for the quarter or YoY comparisons
- • No segment or product line performance data provided
- • $3.5 million settlement payment to Right Value on Feb 28, 2025; $1.5 million accrued liability remains as of Sep 30, 2025
- • Management highlights ongoing unresolved material weakness in internal controls over financial reporting, remediation efforts continuing with no assurance of timely resolution
- • Multiple ongoing litigations including Right Value settlement and Donovitz share repurchase agreement for $18.5 million scheduled Jan 2026, impacting future cash outflows; outlook cautions on legal uncertainties
Risk Factors
- • New risk: Share repurchase program authorized up to $20.0M, with $11.0M remaining as of Sept 30, 2025, introducing potential stock price volatility
- • Material update: Rising tariffs on estradiol from China and trocars from Pakistan increasing raw material costs and supply chain risks
- • Regulatory risk: Complex tariff rules may expose company to civil/criminal trade compliance actions in U.S. and foreign jurisdictions
- • Market risk: Geopolitical tensions and trade disputes causing inflationary pressures, FX volatility, and reduced customer demand
- • Financial risk: Share repurchases totaling 1.01M shares for $3.4M in Q3 2025, affecting cash liquidity and capital allocation
biote Corp. Q3 2025 Quarterly FinancialsXBRL
Revenue
$48M
▼ -6.7% YoY▼ -1.9% QoQ
Net Income
$8M
▲ +4.4% YoY▲ +157.1% QoQ
Operating Margin
17.2%
▼ -647bp YoY▼ -479bp QoQ
Net Margin
17.1%
▲ +180bp YoY▲ +1056bp QoQ
ROE
-11.3%
Total Assets
$111M
EPS (Diluted)
$0.22
▼ -4.3% YoY▲ +144.4% QoQ
Operating Cash Flow
$14M
▼ -9.5% YoY▲ +98.6% QoQ
Source: XBRL data from biote Corp. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on biote Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.